Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Elixirgen Therapeutics, Inc. logo — Reimagine the Power of RNA

Elixirgen Therapeutics, Inc.

Reimagine the Power of RNA

Founded 2017 United States Baltimore, United States 13 employees Series Unknown Total: $25.91M Biotechnology, Health Care +1

General Information

Company Name Elixirgen Therapeutics, Inc.
Founded Year 2017
Location United States Baltimore, United States +1
Employees 13
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series Unknown
Social

Get notified when Elixirgen Therapeutics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a biotechnology startup that is making significant strides in the field of RNA therapeutics. The company's focus lies in developing innovative therapies, including cell and gene therapies, to address a wide range of diseases such as rare and genetic disorders, as well as aging-related issues. They have three key technologies driving their advancements. Their Bobcat mRNA™ technology has demonstrated promising preclinical results in restoring muscular function in models of Duchenne muscular dystrophy, without any associated safety concerns. Another technology, controllable self-replicating (c-srRNA™), aims to improve efficacy by controlling gene expression and reducing off-target effects. Additionally, their ZSCAN4 technology is being tested in a Phase 1/2 clinical trial to extend telomeres in patients with telomere biology disorders, showing initial signs of potential success. Elixirgen Therapeutics, founded in 2017, recently secured a $7.00M Venture Round investment in November 2023, indicating a continued interest from investors in the company's potential. This Baltimore-based company operates from the Science + Technology Park at Johns Hopkins. Elixirgen Therapeutics is certainly a company to watch as it continues to reimagine the power of RNA in therapeutic innovations.

Taxonomy: RNA therapeutics, mRNA technology, cell and gene therapies, rare and genetic diseases, aging-related disorders, Duchenne muscular dystrophy, c-srRNA™ technology, telomere biology disorders, stem cell biology, regenerative medicine, Johns Hopkins Science + Technology Park, biotechnology company, intellectual property, drug development, clinical-stage

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 09 Nov 2023
Debt Financing •••••• - 28 Sep 2022
Venture Round •••••• - 17 Feb 2021
Venture Round •••••• - 02 Dec 2019
Series A •••••• 1
Investor
22 Jun 2018

Elixirgen Therapeutics, Inc. Alternatives & Competitors

Elixirgen Therapeutics, Inc. vs
CorrectSequence Therapeutics
CorrectSequence Therapeutics China

Correct the Gene, Brighten the Future

Series A
10 employees
Biotechnology
Elixirgen Therapeutics, Inc. vs
Imunopharm Technology
Imunopharm Technology China

Make the incurable curable

Series Unknown
19 employees
Biotechnology, Medical Devices

FAQ About Elixirgen Therapeutics, Inc.

Reimagine the Power of RNA
Elixirgen Therapeutics, Inc. was founded in 2017.
Elixirgen Therapeutics, Inc. is headquartered in Baltimore, United States.
Elixirgen Therapeutics, Inc. operates in the following industries: Biotechnology, Health Care, Health and Wellness.
Elixirgen Therapeutics, Inc. has approximately 13 employees.
Elixirgen Therapeutics, Inc. has completed 5 funding rounds, raising a total of $25.91M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Elixirgen Therapeutics, Inc. include CorrectSequence Therapeutics, Imunopharm Technology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elixirgen Therapeutics, Inc. and CorrectSequence Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Elixirgen Therapeutics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy